126 related articles for article (PubMed ID: 37709554)
1. Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.
Atmane MI; Vigneau AL; Beaudry F; Rico C; Boerboom D; Paquet M
Vet Comp Oncol; 2023 Dec; 21(4):634-645. PubMed ID: 37709554
[TBL] [Abstract][Full Text] [Related]
2. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells.
Vigneau AL; Rico C; Boerboom D; Paquet M
Vet Comp Oncol; 2022 Jun; 20(2):437-448. PubMed ID: 34881506
[TBL] [Abstract][Full Text] [Related]
3. Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours.
Rico C; Boerboom D; Paquet M
Vet Comp Oncol; 2018 Dec; 16(4):630-635. PubMed ID: 30117264
[TBL] [Abstract][Full Text] [Related]
4. A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours.
Beffagna G; Sacchetto R; Cavicchioli L; Sammarco A; Mainenti M; Ferro S; Trez D; Zulpo M; Michieletto S; Cecchinato A; Goldschmidt M; Zappulli V
Vet J; 2016 Jan; 207():105-111. PubMed ID: 26626094
[TBL] [Abstract][Full Text] [Related]
5. Wnt/β-Catenin and Hippo Pathway Deregulation in Mammary Tumors of Humans, Dogs, and Cats.
Sammarco A; Gomiero C; Sacchetto R; Beffagna G; Michieletto S; Orvieto E; Cavicchioli L; Gelain ME; Ferro S; Patruno M; Zappulli V
Vet Pathol; 2020 Nov; 57(6):774-790. PubMed ID: 32807036
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.
Guillemette S; Rico C; Godin P; Boerboom D; Paquet M
J Mammary Gland Biol Neoplasia; 2017 Sep; 22(3):203-214. PubMed ID: 28822004
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
[TBL] [Abstract][Full Text] [Related]
8. CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade.
Manuali E; De Giuseppe A; Feliziani F; Forti K; Casciari C; Marchesi MC; Pacifico E; Pawłowski KM; Majchrzak K; Król M
BMC Vet Res; 2012 Jun; 8():86. PubMed ID: 22726603
[TBL] [Abstract][Full Text] [Related]
9. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
Budel SJ; Penning MM; Penning LC
Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours.
Sonzogni-Desautels K; Knapp DW; Sartin E; Doré M
Vet Comp Oncol; 2011 Sep; 9(3):161-71. PubMed ID: 21848619
[TBL] [Abstract][Full Text] [Related]
12. Changes in steroid hormone profile and tumour progression after genistein treatment of canine inflammatory mammary cancer xenotransplanted mice.
Martín-Ruiz A; Peña L; González-Gil A; Silvan G; Caceres S; Illera JC
Res Vet Sci; 2020 Aug; 131():87-91. PubMed ID: 32311590
[TBL] [Abstract][Full Text] [Related]
13. TAZ facilitates breast tumor growth by promoting an immune-suppressive tumor microenvironment.
Gershoni A; Hassin O; Nataraj NB; Baruch S; Avioz-Seligman A; Pirona AC; Fellus-Alyagor L; Meir Salame T; Mukherjee S; Mallel G; Yarden Y; Aylon Y; Oren M
Mol Oncol; 2023 Dec; 17(12):2675-2693. PubMed ID: 37716913
[TBL] [Abstract][Full Text] [Related]
14. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of galectin-1 and galectin-3 in canine non-malignant and malignant mammary tissues and in progression to metastases in mammary tumors.
DE Oliveira JT; DE Matos AJ; Barros R; Ribeiro C; Chen A; Hespanhol V; Rutteman GR; Gärtner F
Anticancer Res; 2014 May; 34(5):2211-21. PubMed ID: 24778023
[TBL] [Abstract][Full Text] [Related]
16. miR-497 induces apoptosis by the IRAK2/NF-κB axis in the canine mammary tumour.
Zhang T; Feng X; Zhou T; Zhou N; Shi X; Zhu X; Qiu J; Deng G; Qiu C
Vet Comp Oncol; 2021 Mar; 19(1):69-78. PubMed ID: 32706167
[TBL] [Abstract][Full Text] [Related]
17. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
18. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of canine mammary tumours on the Canary Archipelago in Spain.
Rodríguez J; Santana Á; Herráez P; Killick DR; de Los Monteros AE
BMC Vet Res; 2022 Jul; 18(1):268. PubMed ID: 35821034
[TBL] [Abstract][Full Text] [Related]
20. Significance of caveolin-1 and matrix metalloproteinase 14 gene expression in canine mammary tumours.
Ebisawa M; Iwano H; Nishikawa M; Tochigi Y; Komatsu T; Endou Y; Hirayama K; Taniyama H; Kadosawa T; Yokota H
Vet J; 2015 Nov; 206(2):191-6. PubMed ID: 26364240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
